{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T18:00:25Z","timestamp":1784311225929,"version":"3.55.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s11882-023-01074-1","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T09:02:58Z","timestamp":1680166978000},"page":"237-248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Comorbid Patient in the Spotlight: Efficacy of Benralizumab on Chronic Rhinosinusitis with Nasal Polyp Outcomes in Presence of Severe Asthma"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5761-7018","authenticated-orcid":false,"given":"Eugenio","family":"De Corso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"D\u2019Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna Elisiana","family":"Carpagnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girolamo","family":"Pelaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"1074_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343\u201373.","journal-title":"Eur Respir J"},{"key":"1074_CR2","doi-asserted-by":"crossref","unstructured":"Hekking P-PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135:896\u2013902.","DOI":"10.1016\/j.jaci.2014.08.042"},{"key":"1074_CR3","first-page":"53","volume":"7","author":"L Massoth","year":"2019","unstructured":"Massoth L, Anderson C, McKinney KA. Asthma and chronic rhinosinusitis: diagnosis and medical management. Med Sci (Basel). 2019;7:53.","journal-title":"Med Sci (Basel)"},{"key":"1074_CR4","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","volume":"9","author":"TM Laidlaw","year":"2021","unstructured":"Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP. Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract. 2021;9:1133\u201341.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1074_CR5","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.jaip.2018.10.016","volume":"7","author":"E Heffler","year":"2019","unstructured":"Heffler E, Blasi F, Latorre M, Menzella F, Paggiaro P, Pelaia G, et al. The severe asthma network in Italy: findings and perspectives. J Allergy Clin Immunol Pract. 2019;7:1462\u20138.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1074_CR6","first-page":"45","volume":"9","author":"C Langdon","year":"2016","unstructured":"Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45\u201353.","journal-title":"J Asthma Allergy"},{"key":"1074_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.105947","volume":"166","author":"GW Canonica","year":"2020","unstructured":"Canonica GW, Malvezzi L, Blasi F, Paggiaro P, Mantero M, Senna G, et al. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: evidences from the Severe Asthma Network Italy (SANI) registry. Respir Med. 2020;166: 105947.","journal-title":"Respir Med"},{"key":"1074_CR8","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jaip.2016.12.027","volume":"5","author":"WW Stevens","year":"2017","unstructured":"Stevens WW, Peters AT, Hirsch AG, Nordberg CM, Schwartz BS, Mercer DG, et al. Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2017;5:1061-1070.e3.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1074_CR9","first-page":"1","volume":"50","author":"WJ Fokkens","year":"2012","unstructured":"Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists Rhinology. 2012;50:1\u201312.","journal-title":"A summary for otorhinolaryngologists Rhinology"},{"key":"1074_CR10","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1398-9995.2005.00725.x","volume":"60","author":"I Alobid","year":"2005","unstructured":"Alobid I, Ben\u00edtez P, Bernal-Sprekelsen M, Roca J, Alonso J, Picado C, et al. Nasal polyposis and its impact on quality of life: comparison between the effects of medical and surgical treatments. Allergy. 2005;60:452\u20138.","journal-title":"Allergy"},{"key":"1074_CR11","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.jaip.2022.03.002","volume":"10","author":"J Mullol","year":"2022","unstructured":"Mullol J, Azar A, Buchheit KM, Hopkins C, Bernstein JA. Chronic rhinosinusitis with nasal polyps: quality of life in the biologics era. J Allergy Clin Immunol Pract. 2022;10:1434-1453.e9.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1074_CR12","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1016\/j.jaip.2022.04.039","volume":"10","author":"J Mullol","year":"2022","unstructured":"Mullol J, Maldonado M, Castillo JA, Miguel-Blanco C, D\u00e1vila I, Dom\u00ednguez-Ortega J, et al. Management of united airway disease focused on patients with asthma and chronic rhinosinusitis with nasal polyps: a systematic review. J Allergy Clin Immunol Pract. 2022;10:2438-2447.e9.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"1074_CR13","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1016\/j.jaip.2022.04.039","volume":"10","author":"J Mullol","year":"2022","unstructured":"Mullol J, Maldonado M, Castillo JA, Miguel-Blanco C, D\u00e1vila I, Dom\u00ednguez-Ortega J, Blanco-Aparicio M. Management of united airway disease focused on patients with asthma and chronic rhinosinusitis with nasal polyps: a systematic review. J Allergy Clin Immunol Pract. 2022;10(9):2438-2447.e9.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1074_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/cea.12472","volume":"45","author":"KE Hulse","year":"2015","unstructured":"Hulse KE, Stevens WW, Tan BK, Schleimer RP. Pathogenesis of nasal polyposis. Clin Exp Allergy. 2015;45:328\u201346.","journal-title":"Clin Exp Allergy"},{"key":"1074_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127228","volume":"10","author":"K H\u00e5kansson","year":"2015","unstructured":"H\u00e5kansson K, Bachert C, Konge L, Thomsen SF, Pedersen AE, Poulsen SS, et al. Airway inflammation in chronic rhinosinusitis with nasal polyps and asthma: the united airways concept further supported. PLoS ONE. 2015;10: e0127228.","journal-title":"PLoS ONE"},{"key":"1074_CR16","doi-asserted-by":"publisher","first-page":"00576","DOI":"10.1183\/23120541.00576-2021","volume":"8","author":"J Maspero","year":"2022","unstructured":"Maspero J, Adir Y, Al-Ahmad M, Celis-Preciado CA, Colodenco FD, Giavina-Bianchi P, et al. Type 2 inflammation in asthma and other airway diseases. ERJ Open Res. 2022;8:00576\u20132021.","journal-title":"ERJ Open Res"},{"key":"1074_CR17","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.anai.2022.01.043","volume":"128","author":"J Mullur","year":"2022","unstructured":"Mullur J, Steger CM, Gakpo D, Bensko JC, Maurer R, Laidlaw TM, et al. Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: efficacy, tolerability, and patient experience. Ann Allergy Asthma Immunol. 2022;128:575\u201382.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1074_CR18","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3390\/jcm11040926","volume":"11","author":"E De Corso","year":"2022","unstructured":"De Corso E, Montuori C, Settimi S, Mele DA, Cantiani A, Corb\u00f2 M, et al. Efficacy of biologics on refractory eosinophilic otitis media associated with bronchial asthma or severe uncontrolled CRSwNP. J Clin Med. 2022;11:926.","journal-title":"J Clin Med"},{"issue":"22","key":"1074_CR19","first-page":"00225","volume":"S0385\u20138146","author":"Y Iino","year":"2022","unstructured":"Iino Y. Eosinophilic otitis media; state-of-the-art diagnosis and treatment. Auris Nasus Larynx. 2022;S0385\u20138146(22):00225\u201335.","journal-title":"Auris Nasus Larynx"},{"key":"1074_CR20","doi-asserted-by":"publisher","first-page":"00024","DOI":"10.1183\/23120541.00024-2015","volume":"1","author":"JC de Groot","year":"2015","unstructured":"de Groot JC, Ten Brinke A, Bel EHD. Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res. 2015;1:00024\u20132015.","journal-title":"ERJ Open Res"},{"key":"1074_CR21","doi-asserted-by":"crossref","unstructured":"Heaney LG, Perez de Llano L, Al-Ahmad M, Backer V, Busby J, Canonica GW, et al. Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort. Chest. 2021;160:814\u201330.","DOI":"10.1016\/j.chest.2021.04.013"},{"key":"1074_CR22","first-page":"1375","volume":"8","author":"A Bakakos","year":"2019","unstructured":"Bakakos A, Loukides S, Bakakos P. Severe eosinophilic asthma. J. Clin Med. 2019;8:1375.","journal-title":"Clin Med"},{"key":"1074_CR23","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/all.13342","volume":"73","author":"S Maio","year":"2018","unstructured":"Maio S, Baldacci S, Bresciani M, Simoni M, Latorre M, Murgia N, et al. RItA: the Italian severe\/uncontrolled asthma registry. Allergy. 2018;73:683\u201395.","journal-title":"Allergy"},{"key":"1074_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12931-022-01952-8","volume":"23","author":"F Menzella","year":"2022","unstructured":"Menzella F, Bargagli E, Aliani M, Bracciale P, Brussino L, Caiaffa MF, et al. ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study. Respir Res. 2022;23:36.","journal-title":"Respir Res"},{"key":"1074_CR25","doi-asserted-by":"publisher","first-page":"4839230","DOI":"10.1155\/2018\/4839230","volume":"2018","author":"C Pelaia","year":"2018","unstructured":"Pelaia C, Calabrese C, Vatrella A, Busceti MT, Garofalo E, Lombardo N, et al. Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma. Biomed Res Int. 2018;2018:4839230.","journal-title":"Biomed Res Int"},{"key":"1074_CR26","doi-asserted-by":"publisher","first-page":"2004306","DOI":"10.1183\/13993003.04306-2020","volume":"59","author":"R Dagher","year":"2022","unstructured":"Dagher R, Kumar V, Copenhaver AM, Gallagher S, Ghaedi M, Boyd J, et al. Novel mechanisms of action contributing to benralizumab\u2019s potent anti-eosinophilic activity. Eur Respir J. 2022;59:2004306.","journal-title":"Eur Respir J"},{"key":"1074_CR27","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.3390\/biomedicines9101497","volume":"9","author":"A Matucci","year":"2021","unstructured":"Matucci A, Vivarelli E, Nencini F, Maggi E, Vultaggio A. Strategies targeting type 2 inflammation: from monoclonal antibodies to JAK-inhibitors. Biomedicines. 2021;9:1497.","journal-title":"Biomedicines"},{"issue":"5","key":"1074_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12049","volume":"11","author":"C M\u00fcmmler","year":"2021","unstructured":"M\u00fcmmler C, D\u00fcnzelmann K, Kneidinger N, Barnikel M, Munker D, Gr\u00f6ger M, Canis M, Behr J, Koch A, Haubner F, Milger K. Real-life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNP. Clin Transl Allergy. 2021;11(5): e12049.","journal-title":"Clin Transl Allergy"},{"key":"1074_CR29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2147\/JAA.S227170","volume":"12","author":"JM FitzGerald","year":"2019","unstructured":"FitzGerald JM, Bleecker ER, Bourdin A, Busse WW, Ferguson GT, Brooks L, et al. Two-year integrated efficacy and safety analysis of benralizumab in severe asthma. J Asthma Allergy. 2019;12:401\u201313.","journal-title":"J Asthma Allergy"},{"key":"1074_CR30","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","volume":"159","author":"JE Kavanagh","year":"2021","unstructured":"Kavanagh JE, Hearn AP, Dhariwal J, d\u2019Ancona G, Douiri A, Roxas C, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021;159:496\u2013506.","journal-title":"Chest"},{"key":"1074_CR31","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.anai.2022.02.017","volume":"128","author":"Y Chung","year":"2022","unstructured":"Chung Y, Katial R, Mu F, Cook EE, Young J, Yang D, et al. Real-world effectiveness of benralizumab: results from the ZEPHYR 1 Study. Ann Allergy Asthma Immunol. 2022;128:669-676.e6.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1074_CR32","doi-asserted-by":"publisher","first-page":"1800936","DOI":"10.1183\/13993003.00936-2018","volume":"52","author":"ER Bleecker","year":"2018","unstructured":"Bleecker ER, Wechsler ME, FitzGerald JM, Menzies-Gow A, Wu Y, Hirsch I, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018;52:1800936.","journal-title":"Eur Respir J"},{"key":"1074_CR33","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1016\/j.jaip.2021.08.004","volume":"9","author":"S Nolasco","year":"2021","unstructured":"Nolasco S, Crimi C, Pelaia C, Benfante A, Caiaffa MF, Calabrese C, et al. Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: a real-world multicenter study. J Allergy Clin Immunol Pract. 2021;9:4371-4380.e4.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1074_CR34","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3949\/ccjm.87a.19136","volume":"87","author":"Y Mauer","year":"2020","unstructured":"Mauer Y, Taliercio RM. Managing adult asthma: the 2019 GINA guidelines. Cleve Clin J Med. 2020;87:569\u201375.","journal-title":"Cleve Clin J Med"},{"key":"1074_CR35","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"1074_CR36","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jech.52.6.377","volume":"52","author":"SH Downs","year":"1998","unstructured":"Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52:377\u201384.","journal-title":"J Epidemiol Community Health"},{"key":"1074_CR37","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","volume":"9","author":"TW Harrison","year":"2021","unstructured":"\u2022\u2022 Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med. 2021;9:260\u201374. First randomized clinical trial assessing the efficacy and safety of benralizumab in SEA patients with a subpopulation diagnosed with CRSwNP.","journal-title":"Lancet Respir Med"},{"key":"1074_CR38","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/all.14902","volume":"77","author":"GW Canonica","year":"2022","unstructured":"Canonica GW, Harrison TW, Chanez P, Menzella F, Louis R, Cosio BG, et al. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis. Allergy. 2022;77:150\u201361.","journal-title":"Allergy"},{"key":"1074_CR39","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1177\/1945892420978351","volume":"35","author":"C Chitguppi","year":"2021","unstructured":"Chitguppi C, Patel P, Gandler A, Murphy K, Khoury MdT, Monostra P, et al. Effect of benralizumab in patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: a case series. Am J Rhinol Allergy. 2021;35:559\u201367.","journal-title":"Am J Rhinol Allergy"},{"key":"1074_CR40","doi-asserted-by":"crossref","unstructured":"Barroso B, Valverde-Monge M, Alobid I, Olaguibel JM, Rial MJ, Quirce S, et al. Smell improvement by anti-IgE and anti-IL 5 biologics in patients with CRSwNP and severe asthma. A real life study. J Investig Allergol Clin Immunol. 2022;0.","DOI":"10.22541\/au.163664298.87262503\/v1"},{"key":"1074_CR41","first-page":"575","volume":"60","author":"C Santomasi","year":"2022","unstructured":"Santomasi C, Buonamico E, Dragonieri S, Lulaj E, Maselli L, Iorillo I, et al. Effects of benralizumab in patients affected by severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps. Eur Respir J. 2022;60:575.","journal-title":"Eur Respir J"},{"key":"1074_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.106080","volume":"171","author":"D Bagnasco","year":"2020","unstructured":"\u2022\u2022 Bagnasco D, Brussino L, Bonavia M, Calzolari E, Caminati M, Caruso C, et al. Efficacy of benralizumab in severe asthma in real life and focus on nasal polyposis. Respir Med. 2020;171: 106080. Benralizumab confirmed its efficacy in severe asthma and nasal polyposis. The efficacy of benralizumab in reducing steroid dependence was even higher in patients with polyposis.","journal-title":"Respir Med"},{"key":"1074_CR43","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.imlet.2022.06.009","volume":"248","author":"C Cavaliere","year":"2022","unstructured":"\u2022 Cavaliere C, Segatto M, Ciofalo A, Colizza A, Minni A, Messineo D, et al. Benralizumab reduces eosinophils and inflammatory markers in patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: a pilot real-life study. Immunol Lett. 2022;248:70\u20137. Pilot real-life study conducted with an anti-IL5R monoclonal antibody in severe eosinophilic asthma and severe CRSwNP patients showing that this treatment can induce benefit in both diseases.","journal-title":"Immunol Lett"},{"key":"1074_CR44","doi-asserted-by":"publisher","first-page":"205873842095085","DOI":"10.1177\/2058738420950851","volume":"34","author":"N Lombardo","year":"2020","unstructured":"\u2022 Lombardo N, Pelaia C, Ciriolo M, Della Corte M, Piazzetta G, Lobello N, et al. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma. Int J Immunopathol Pharmacol. 2020;34:2058738420950851. Real-life study evaluating effectiveness of the IL-5R blocker benralizumab on chronic rhinosinusitis with nasal polyposis (CRSwNP), associated with severe eosinophilic allergic asthma.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"1074_CR45","doi-asserted-by":"crossref","unstructured":"Tiotiu A, Mendez-Brea P, Ioan I, Romero-Fernandez R, Oster JP, Hoang T-C-T, et al. Real-life effectiveness of benralizumab, mepolizumab and omalizumab in severe allergic asthma associated with nasal polyps. Clin Rev Allergy Immunol. 2022.","DOI":"10.1183\/13993003.congress-2022.758"},{"key":"1074_CR46","first-page":"2353","volume":"34","author":"E Buonamico","year":"2020","unstructured":"Buonamico E, Dragonieri S, Sciancalepore PI, Carrat\u00f9 P, Carpagnano GE, Resta O, et al. Assessment of eosinophilic nasal inflammation in patients with severe asthma and nasal polyposis before and after six months of therapy with benralizumab. J Biol Regul Homeost Agents. 2020;34:2353\u20137.","journal-title":"J Biol Regul Homeost Agents"},{"key":"1074_CR47","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","volume":"149","author":"C Bachert","year":"2022","unstructured":"\u2022\u2022 Bachert C, Han JK, Desrosiers MY, Gevaert P, Heffler E, Hopkins C, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022;149:1309-1317.e12. Randomized clinical trial assessing the efficacy and safety of benralizumab-mediated eosinophil depletion for treating CRSwNP.","journal-title":"J Allergy Clin Immunol"},{"key":"1074_CR48","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/cea.13852","volume":"51","author":"J Tversky","year":"2021","unstructured":"Tversky J, Lane AP, Azar A. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo-controlled trial. Clin Exp Allergy. 2021;51:836\u201344.","journal-title":"Clin Exp Allergy"},{"key":"1074_CR49","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1177\/19458924211009429","volume":"35","author":"T Takabayashi","year":"2021","unstructured":"\u2022\u2022 Takabayashi T, Asaka D, Okamoto Y, Himi T, Haruna S, Yoshida N, et al. A phase II, multicenter, randomized, placebo-controlled study of benralizumab, a humanized anti-IL-5R alpha monoclonal antibody, in patients with eosinophilic chronic rhinosinusitis. Am J Rhinol Allergy. 2021;35:861\u201370. Randomized clinical trial assessing the efficacy and safety of benralizumab","journal-title":"Am J Rhinol Allergy"},{"key":"1074_CR50","doi-asserted-by":"publisher","first-page":"465","DOI":"10.4168\/aair.2022.14.5.465","volume":"14","author":"SK Yang","year":"2022","unstructured":"Yang SK, Cho S-H, Kim DW. Interpretation of clinical efficacy of biologics in chronic rhinosinusitis with nasal polyps via understanding the local and systemic pathomechanisms. Allergy Asthma Immunol Res. 2022;14:465\u201378.","journal-title":"Allergy Asthma Immunol Res"},{"key":"1074_CR51","doi-asserted-by":"publisher","first-page":"435","DOI":"10.14639\/0392-100X-N0716","volume":"40","author":"F Bandi","year":"2020","unstructured":"Bandi F, Gallo S, Preti A, Mozzanica F, Visca D, Marelli M, et al. Effects of biological therapies on chronic rhinosinusitis in severe asthmatic patients. Acta Otorhinolaryngol Ital. 2020;40:435\u201343.","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"1074_CR52","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/lio2.32","volume":"1","author":"SK Dennis","year":"2016","unstructured":"Dennis SK, Lam K, Luong A. A review of classification schemes for chronic rhinosinusitis with nasal polyposis endotypes. Laryngoscope Investig Otolaryngol. 2016;1:130\u20134.","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"1074_CR53","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3390\/jpm12071096","volume":"12","author":"V Seccia","year":"2022","unstructured":"Seccia V, D\u2019Amato M, Scioscia G, Bagnasco D, Di Marco F, Fadda G, et al. Management of patients with severe asthma and chronic rhinosinusitis with nasal polyps: a multidisciplinary shared approach. J Pers Med. 2022;12:1096.","journal-title":"J Pers Med"},{"key":"1074_CR54","doi-asserted-by":"crossref","unstructured":"De Corso E, Bellocchi G, De Benedetto M, Lombardo N, Macchi A, Malvezzi L, et al. Biologics for severe uncontrolled chronic rhinosinusitis with nasal polyps: a change management approach. Consensus of the Joint Committee of Italian Society of Otorhinolaryngology on biologics in rhinology. Acta Otorhinolaryngol Ital. 2022;42:1\u201316.","DOI":"10.14639\/0392-100X-N1614"},{"key":"1074_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2022.881218","volume":"3","author":"M D\u2019Amato","year":"2022","unstructured":"D\u2019Amato M, Menzella F, Altieri E, Bargagli E, Bracciale P, Brussino L, et al. Benralizumab in patients with severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: an ANANKE study post-hoc analysis. Front Allergy. 2022;3: 881218.","journal-title":"Front Allergy"},{"key":"1074_CR56","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1016\/j.jaip.2021.07.049","volume":"9","author":"I Briegel","year":"2021","unstructured":"Briegel I, Felicio-Briegel A, Mertsch P, Kneidinger N, Haubner F, Milger K. Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP. J Allergy Clin Immunol Pract. 2021;9:4477\u20139.","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-023-01074-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-023-01074-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-023-01074-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T10:39:25Z","timestamp":1684924765000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-023-01074-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1074"],"URL":"https:\/\/doi.org\/10.1007\/s11882-023-01074-1","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"assertion":[{"value":"14 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"EDC: lecture fees and participations in experts\u2019 board meeting of GSK, Novartis, Sanofi, Astrazeneca. MDA: speaker and advisory board fees from AstraZeneca, Glaxo Smith Kline and Sanofi. GEC: lecture fees and participations in experts board meeting of GSK, Chiesi, Grifols, Boehringer Ingelheim Sanofi, Astrazeneca Girolamo Pelaia: lecture fees and participations in expert board meetings of AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Guidotti, Menarini, Novartis, Sanofi. MB: speaker and advisory board fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Glaxo Smith Kline, Menarini and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}